Share on LinkedInShare on LinkedIn

ARTICLE · 13 JULY 2022

Federal Circuit Reconsiders Written Description Support For Negative Limitation

The original Federal Circuit decision in Novartis Pharms. Corp. v. Accord Healthcare, Inc. was on the list of "written description" cases I covered in several conference programs this spring.

United StatesIntellectual Property

The original Federal Circuit decision in Novartis Pharms. Corp. v. Accord Healthcare, Inc. was on the list of "written description" cases I covered in several conference programs this spring. It was interesting because written description support was found for a negative limitation that was not mentioned in the application, based in part on a prophetic example that did not include the step excluded from the claims. Now that the panel has granted rehearing and reached a different conclusion, I want to make sure I set the record straight here as well.

The Patent At Issue

The patent at issues was U.S. Patent No. 9,187,405, which was listed in the Orange Book for Novartis's GILENYA® fingolimod product, which is approved for the treatment of relapsing forms of multiple sclerosis. Claim 1 is reproduced below, with emphasis showing the negative limitation at issue:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from